Brief: FDA Approves Edwards Lifesciences' Sapien M3 Mitral Valve Replacement System As First Transseptal Transcatheter Therapy
23/12/2025 14:03
Dec 23 (Reuters) - Edwards Lifesciences Corp EW.N: FDA APPROVES EDWARDS LIFESCIENCES' SAPIEN M3 MITRAL VALVE REPLACEMENT SYSTEM AS FIRST TRANSSEPTAL TRANSCATHETER THERAPY Source text: ID:nBw75FQyKa Further company coverage: EW.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edwards Lifesciences
See all newsFDA flags Edwards heart-valve delivery system issue after death, injury (updated)
FDA flags Edwards heart-valve delivery system issue after death, injury
Brief: FDA Aware Edwards Lifesciences Issued Letter Recommending Some Delivery Systems Used For Sapien M3 Transcatheter Mitral Valve Replacement Be Removed
Brief: Edwards Lifesciences Corporation - Maintains Confidence In Financial Guidance For 2026
U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United Rentals